Infectious diseases are caused by pathogenic microorganisms, such as viruses, bacteria, parasites, or fungi. Diseases such as HIV/AIDS, tuberculosis, malaria, and emerging infectious diseases continue to cause immense human suffering and hinder economic and social progress, especially in developing countries. Thus, the rising prevalence of such infectious diseases worldwide is expected to boost the growth of the infectious disease therapeutics market over the forecast period.
Infectious disease therapeutics are used for the treatment of various infectious diseases such as bacterial, viral, and fungal infections. These therapeutics include antibiotics, antivirals, antifungals, antiprotozoals, and other drugs. Antibiotics are one of the most commonly used infectious disease therapeutics for treating bacterial infections such as pneumonia, urinary tract infections, and septicemia. The increasing prevalence of antibiotic-resistant bacterial strains is fueling the demand for new and effective antibiotics.
The infectious disease therapeutics market is estimated to be valued at US$ 170.67 Bn in 2023 and is expected to exhibit a CAGR of 3.7% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The rising threat of antimicrobial resistance is one of the key trends in the infectious disease therapeutics market. Over the years, many bacterial and fungal strains have developed resistance to antibiotics and antimicrobial drugs. According to the Centers for Disease Control and Prevention (CDC), over 2.8 million antibiotic-resistant infections occur in the United States each year, with more than 35,000 people dying as a result. The rising antimicrobial resistance is driving research and development of novel classes of antibiotics effective against drug-resistant pathogens. Companies are focusing on developing combination therapies as well as alternate antimicrobial therapeutic strategies to fight resistant infections. Several biotech companies are also actively engaged in developing vaccines targeting drug-resistant infectious microbes.
Porter's Analysis
Threat of new entrants: The threat of new entrants is moderate due to high R&D costs and stringent regulations. However, there is potential for biotech startups to disrupt the market with new drugs.
Bargaining power of buyers: The bargaining power of buyers is moderate since diseases cannot be selectively treated. However, buyers can negotiate on drug prices to an extent.
Bargaining power of suppliers: Suppliers of raw materials have moderate bargaining power due to limited availability of resources and formulations. However, suppliers are dependent on major players for volume orders.
Threat of new substitutes: The threat of new substitutes is low as each drug treats a specific disease with distinct mechanisms of action.
Competitive rivalry: Fierce competition exists between major players.
SWOT Analysis
Strengths: Strong R&D pipelines, global presence, brand recognition and large product portfolios allow major players to dominate the market.
Weaknesses: High R&D costs, regulatory hurdles and patent cliffs on blockbuster drugs impact profits. Dependence on government reimbursements poses pricing challenges.
Opportunities: Growing disease incidence, demand in developing nations, supportive regulatory environment and emerging technologies will drive market growth.
Threats: Generic competition, pricing pressures, stringent regulations and political uncertainties pose significant threats.
Key Takeaways
Market size: The global infectious disease therapeutics market is expected to witness growth at a CAGR of 3.7% over the forecast period owing to growing disease incidence and demand in developing regions.
Regional analysis: North America dominates the market currently due to supportive healthcare infrastructure and regulatory policies. However, Asia Pacific is expected to grow the fastest through 2030 with increasing healthcare spending and demand in China and India.
Key players: Key players operating in the infectious disease therapeutics market are Novartis International AG, Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceutical, F. Hoffmann-La Roche AG, BioCryst Pharmaceuticals, Inc., and Boehringer Ingelheim GmbH. among others. Major players focus on collaborations and M&As to enhance pipelines and market share.
The global infectious disease diagnostics market was valued at USD 13.93 Billion in 2016 and projected to reach USD 19.35 Billion in 2022, at a CAGR of 5.6%.
The base year considered for the study is 2016, and the forecast for the market size is provided for the period between 2017 and 2022.
Growth in this market is primarily driven by the increasing global prevalence of infectious diseases, shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnosticsDownload PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589Global Market Segmentation:The market is broadly segmented into assays, kits, & reagents; instruments; and services & software based on product & service.
The assays, kits, & reagents segment accounted for the largest share of the global market and is expected to register the highest CAGR during the forecast period.
The increasing number of infectious disease diagnostic tests carried out; easy accessibility to a wide range of reagents; and the growing need for reliable, specific, and faster detection of infectious diseases in the early stages are the key factors driving the IDD assays, kits, & reagents market.Based on the disease type, the market is segmented into hepatitis, HIV, HAIs, CT/NG, HPV, TB, Influenza, and other diseases.
The hepatitis diagnostics segment accounted for the largest share of the global market in 2017.
